JP2018506586A - プラジカンテル及びその中間体化合物の製造方法 - Google Patents
プラジカンテル及びその中間体化合物の製造方法 Download PDFInfo
- Publication number
- JP2018506586A JP2018506586A JP2017560847A JP2017560847A JP2018506586A JP 2018506586 A JP2018506586 A JP 2018506586A JP 2017560847 A JP2017560847 A JP 2017560847A JP 2017560847 A JP2017560847 A JP 2017560847A JP 2018506586 A JP2018506586 A JP 2018506586A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- reaction
- solvent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 111
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960002957 praziquantel Drugs 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 238000006243 chemical reaction Methods 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 73
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 26
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims abstract description 13
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims abstract description 10
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005917 acylation reaction Methods 0.000 claims abstract description 6
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 6
- 238000006467 substitution reaction Methods 0.000 claims abstract description 6
- 238000006482 condensation reaction Methods 0.000 claims abstract description 5
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 32
- 239000005457 ice water Substances 0.000 claims description 31
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 29
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 25
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 18
- 239000011734 sodium Substances 0.000 claims description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 12
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 11
- 229940011051 isopropyl acetate Drugs 0.000 claims description 11
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 9
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 239000007800 oxidant agent Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 8
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 claims description 6
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 239000003096 antiparasitic agent Substances 0.000 claims description 6
- 229940125687 antiparasitic agent Drugs 0.000 claims description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 6
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 6
- 150000008282 halocarbons Chemical class 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 150000002430 hydrocarbons Chemical class 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 claims description 5
- 239000007810 chemical reaction solvent Substances 0.000 claims description 5
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- 229940043279 diisopropylamine Drugs 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 3
- VMOWKUTXPNPTEN-UHFFFAOYSA-N n,n-dimethylpropan-2-amine Chemical compound CC(C)N(C)C VMOWKUTXPNPTEN-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 11
- 239000000543 intermediate Substances 0.000 abstract description 11
- 239000002994 raw material Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 42
- 239000007787 solid Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 6
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 238000009776 industrial production Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 3
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
- -1 4-methylbenzenesulfonyloxy Chemical group 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- WDLUEZJSSHTKAP-UHFFFAOYSA-N acetaldehyde;1,1-diethoxyethane Chemical class CC=O.CCOC(C)OCC WDLUEZJSSHTKAP-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 201000004409 schistosomiasis Diseases 0.000 description 2
- UXBLSWOMIHTQPH-UHFFFAOYSA-N 4-acetamido-TEMPO Chemical compound CC(=O)NC1CC(C)(C)N([O])C(C)(C)C1 UXBLSWOMIHTQPH-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- FXTYNGVTUXVBEK-UHFFFAOYSA-N OCCCN(CC(NCCc1ccccc1)=O)C(C1CCCCC1)=O Chemical compound OCCCN(CC(NCCc1ccccc1)=O)C(C1CCCCC1)=O FXTYNGVTUXVBEK-UHFFFAOYSA-N 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 241001442514 Schistosomatidae Species 0.000 description 1
- 208000002848 Schistosomiasis mansoni Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- QYTDEUPAUMOIOP-UHFFFAOYSA-N TEMPO Chemical compound CC1(C)CCCC(C)(C)N1[O] QYTDEUPAUMOIOP-UHFFFAOYSA-N 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 229950009390 symclosene Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
1)β-フェネチルアミン及びクロロアセチルクロリドを、アルカリ性物質の存在下で縮合反応に供し、式IIの化合物を得る工程と、
本発明は、以下の実施例によって更に説明されるが、以下の実施例は、本発明に対するいかなる制限としても理解されるべきではない。当業者は、先行技術に従って修正又は改良を行うことができ、これらは本発明の範囲内である。保護範囲及び精神は、特許請求の範囲及びそれと均等な技術的解決法によって定義される。
TCCA:トリクロロイソシアヌル酸
SO3-Py:三酸化硫黄-ピリジン
Claims (25)
- 工程1)、工程2)、工程3)、工程4)又は工程5)が、溶媒なしで行われるか、又は溶媒として少なくとも1種の非プロトン性有機溶媒を用いて行われることを特徴とする、請求項1に記載の方法。
- 工程2)が溶媒なしで行われ、工程1)、工程3)、工程4)又は工程5)が、溶媒として少なくとも1種の非プロトン性有機溶媒を用いて行われることを特徴とする、請求項1に記載の方法。
- 前記非プロトン性有機溶媒が、エーテル溶媒、芳香族炭化水素溶媒、炭化水素若しくはハロゲン化炭化水素溶媒又はエステル溶媒からなる群から選択される少なくとも1種であることを特徴とする、請求項2又は3に記載の方法。
- 前記エーテル溶媒が、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシルエタン、メチルtert-ブチルエーテル又は2-メチルテトラヒドロフランからなる群から選択され、好ましくはメチルtert-ブチルエーテルであり、
前記芳香族炭化水素溶媒が、ベンゼン、トルエン、エチルベンゼン又はキシレンからなる群から選択され、好ましくはトルエンであり、
前記炭化水素又はハロゲン化炭化水素溶媒が、n-ヘキサン、シクロヘキサン、n-ヘプタン、ジクロロメタン、トリクロロメタン又はジクロロエタンからなる群から選択され、好ましくはジクロロメタンであり、
前記エステル溶媒が、ギ酸メチル、ギ酸エチル、酢酸メチル、酢酸エチル又は酢酸イソプロピルからなる群から選択され、好ましくは酢酸エチル又は酢酸イソプロピルである
ことを特徴とする、請求項4に記載の方法。 - 工程1)、工程2)、工程3)、工程4)又は工程5)の反応温度が、-10℃〜100℃、好ましくは0℃〜40℃、より好ましくは5℃〜15℃、最も好ましくは10℃〜15℃であることを特徴とする、請求項1に記載の方法。
- 工程1)、工程2)、工程3)、工程4)又は工程5)が、氷水浴中、室温又は0℃〜40℃で行われることを特徴とする、請求項1に記載の方法。
- 工程1)、工程3)又は工程5)が、氷水浴中で行われ、工程2)が、室温で行われ、工程4)が、0℃〜40℃、好ましくは5℃〜15℃、より好ましくは10℃〜15℃で行われることを特徴とする、請求項1に記載の方法。
- 工程1)及び工程3)における前記アルカリ性物質が、トリエチルアミン、イミダゾール、ピリジン、2-メチルピリジン、2,6-ジメチルピリジン、4-ジメチルアミノピリジン、ジイソプロピルアミン、ジメチルイソプロピルアミン、ジイソプロピルエチルアミン、NaOH、Na2CO3、NaHCO3、KOH又はK2CO3からなる群からそれぞれ独立して選択される1種又は複数であり、好ましくはトリエチルアミン、NaOH、Na2CO3、NaHCO3、KOH又はK2CO3からなる群から選択される1種又は複数であることを特徴とする、請求項1に記載の方法。
- 工程2)において、前記式IIの化合物のエタノールアミンに対するモル比が、1:2〜1:15、好ましくは1:3〜1:8であることを特徴とする、請求項1に記載の方法。
- 工程4)の前記酸化剤が、NaClO/TEMPO/NaBr、Ca(ClO)2/TEMPO/NaBr、TCCA/TEMPO、DMSO/SO3-Py/Et3N、NaNO2/FeCl3/TEMPO/空気、NaNO2/FeCl3/TEMPO/O2からなる群から選択される少なくとも1つの群であることを特徴とする、請求項1に記載の方法。
- 工程5)の前記環化剤が、ギ酸、酢酸、トリフルオロ酢酸、メタンスルホン酸、トリフルオロメタンスルホン酸、p-トルエンスルホン酸、ベンゼンスルホン酸、過塩素酸又は濃硫酸からなる群から選択される1種又は複数であり、好ましくは濃硫酸又はメタンスルホン酸であることを特徴とする、請求項1に記載の方法。
- 工程1)及び工程3)における前記アルカリ性物質が、トリエチルアミン、イミダゾール、ピリジン、2-メチルピリジン、2,6-ジメチルピリジン、4-ジメチルアミノピリジン、ジイソプロピルアミン、ジメチルイソプロピルアミン、ジイソプロピルエチルアミン、NaOH、Na2CO3、NaHCO3、KOH又はK2CO3からなる群からそれぞれ独立して選択される1種又は複数であり、好ましくはトリエチルアミン、NaOH、Na2CO3、NaHCO3、KOH又はK2CO3からなる群から選択される1種又は複数であることを特徴とする、請求項14に記載の製造方法。
- 工程2)において、前記式IIの化合物のエタノールアミンに対するモル比が、1:2〜1:15、好ましくは1:3〜1:8であることを特徴とする、請求項14に記載の製造方法。
- 工程1)、工程2)又は工程3)が溶媒なしで行われるか又は反応溶媒として少なくとも1種の非プロトン性有機溶媒を用いて行われることを特徴とする、請求項14に記載の製造方法。
- 前記非プロトン性有機溶媒が、エーテル溶媒、芳香族炭化水素溶媒、炭化水素若しくはハロゲン化炭化水素溶媒又はエステル溶媒からなる群から選択される少なくとも1種であることを特徴とする、請求項17に記載の製造方法。
- 前記エーテル溶媒が、テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシルエタン、メチルtert-ブチルエーテル又は2-メチルテトラヒドロフランからなる群から選択され、好ましくはメチルtert-ブチルエーテルであり、
前記芳香族炭化水素溶媒が、ベンゼン、トルエン、エチルベンゼン又はキシレンからなる群から選択され、好ましくはトルエンであり、
前記炭化水素又はハロゲン化炭化水素溶媒が、n-ヘキサン、シクロヘキサン、n-ヘプタン、ジクロロメタン、トリクロロメタン又はジクロロエタンからなる群から選択され、好ましくはジクロロメタンであり、
前記エステル溶媒が、ギ酸メチル、ギ酸エチル、酢酸メチル、酢酸エチル又は酢酸イソプロピルからなる群から選択され、好ましくは酢酸エチル又は酢酸イソプロピルである
ことを特徴とする、請求項18に記載の製造方法。 - 工程1)、工程2)又は工程3)の反応温度が、-10℃〜100℃、好ましくは0℃〜40℃、より好ましくは5℃〜15℃、最も好ましくは10℃〜15℃であることを特徴とする、請求項14に記載の製造方法。
- 抗寄生虫薬であるプラジカンテルの製造における、請求項13に記載の式IVの中間体化合物の使用。
- 前記酸化剤が、NaClO/TEMPO/NaBr、Ca(ClO)2/TEMPO/NaBr、TCCA/TEMPO及びDMSO/SO3-Py/Et3N、NaNO2/FeCl3/TEMPO/空気、NaNO2/FeCl3/TEMPO/O2からなる群から選択される少なくとも1つの群であることを特徴とする、請求項23に記載の製造方法。
- 抗寄生虫薬であるプラジカンテルの製造における、請求項22に記載の式Vの中間体化合物の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/072830 WO2016127350A1 (zh) | 2015-02-12 | 2015-02-12 | 一种吡喹酮的制备方法及其中间体化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018506586A true JP2018506586A (ja) | 2018-03-08 |
JP6359208B2 JP6359208B2 (ja) | 2018-07-18 |
Family
ID=56615192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017560847A Active JP6359208B2 (ja) | 2015-02-12 | 2015-02-12 | プラジカンテル及びその中間体化合物の製造方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10035798B2 (ja) |
EP (1) | EP3257852B1 (ja) |
JP (1) | JP6359208B2 (ja) |
KR (1) | KR101960347B1 (ja) |
CN (1) | CN107406444B (ja) |
BR (1) | BR112017017066B1 (ja) |
RU (1) | RU2671202C1 (ja) |
WO (1) | WO2016127350A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6359208B2 (ja) * | 2015-02-12 | 2018-07-18 | 浙江▲海▼正▲薬▼▲業▼股▲フン▼有限公司 | プラジカンテル及びその中間体化合物の製造方法 |
CN106866663A (zh) * | 2017-03-15 | 2017-06-20 | 江苏诚信药业有限公司 | 一种吡喹酮合成的工艺方法 |
CN109336885B (zh) * | 2018-11-16 | 2021-04-13 | 周口师范学院 | 一种吡喹酮的制备方法 |
CN112811995A (zh) * | 2021-01-14 | 2021-05-18 | 惠泽化学科技(濮阳)有限公司 | 一种4-取代基环己酮类液晶中间体的合成方法 |
CN114195783B (zh) * | 2021-12-29 | 2022-11-25 | 河北嘉一药业有限公司 | 一种左旋吡喹酮的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020076486A (ko) * | 2001-03-28 | 2002-10-11 | 조수동 | 프탈이미드를 이용한 프라지콴텔의 제조방법 |
CN1683346A (zh) * | 2005-03-01 | 2005-10-19 | 江苏工业学院 | 吡喹酮合成工艺 |
CN103044422A (zh) * | 2012-12-27 | 2013-04-17 | 威海迪之雅医药化工开发有限公司 | 一种吡喹酮的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2504250A1 (de) | 1975-02-01 | 1976-08-05 | Merck Patent Gmbh | Tetrahydroisochinolin-derivate und verfahren zu ihrer herstellung |
DE2508947C3 (de) | 1975-03-01 | 1982-02-25 | Merck Patent Gmbh, 6100 Darmstadt | Verfahren zur Herstellung von 4-Oxo-1,2,3,6,7, 11b-hexahydro-4H-pyrazino [2,1-a] isochinolinen |
PL2118055T3 (pl) * | 2007-02-09 | 2014-01-31 | Zoetis Uk Ltd | Środki przeciwpasożytnicze |
WO2012081035A2 (en) * | 2010-12-13 | 2012-06-21 | Sequent Scientific Limited | A process for preparation of praziquantel |
CN103739601A (zh) * | 2013-12-12 | 2014-04-23 | 江苏诚信制药有限公司 | 一种制备吡喹酮的方法 |
JP6359208B2 (ja) * | 2015-02-12 | 2018-07-18 | 浙江▲海▼正▲薬▼▲業▼股▲フン▼有限公司 | プラジカンテル及びその中間体化合物の製造方法 |
-
2015
- 2015-02-12 JP JP2017560847A patent/JP6359208B2/ja active Active
- 2015-02-12 EP EP15881512.6A patent/EP3257852B1/en active Active
- 2015-02-12 US US15/550,190 patent/US10035798B2/en active Active
- 2015-02-12 BR BR112017017066-3A patent/BR112017017066B1/pt active IP Right Grant
- 2015-02-12 WO PCT/CN2015/072830 patent/WO2016127350A1/zh active Application Filing
- 2015-02-12 RU RU2017131412A patent/RU2671202C1/ru active
- 2015-02-12 KR KR1020177025578A patent/KR101960347B1/ko active IP Right Grant
- 2015-02-12 CN CN201580075573.3A patent/CN107406444B/zh active Active
-
2018
- 2018-06-21 US US16/014,678 patent/US10508112B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020076486A (ko) * | 2001-03-28 | 2002-10-11 | 조수동 | 프탈이미드를 이용한 프라지콴텔의 제조방법 |
CN1683346A (zh) * | 2005-03-01 | 2005-10-19 | 江苏工业学院 | 吡喹酮合成工艺 |
CN103044422A (zh) * | 2012-12-27 | 2013-04-17 | 威海迪之雅医药化工开发有限公司 | 一种吡喹酮的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US10035798B2 (en) | 2018-07-31 |
EP3257852A4 (en) | 2018-08-15 |
BR112017017066B1 (pt) | 2022-11-29 |
EP3257852A1 (en) | 2017-12-20 |
BR112017017066A2 (pt) | 2018-04-10 |
US20180030049A1 (en) | 2018-02-01 |
JP6359208B2 (ja) | 2018-07-18 |
CN107406444B (zh) | 2019-07-23 |
WO2016127350A1 (zh) | 2016-08-18 |
KR20170117165A (ko) | 2017-10-20 |
US10508112B2 (en) | 2019-12-17 |
EP3257852B1 (en) | 2020-01-01 |
CN107406444A (zh) | 2017-11-28 |
KR101960347B1 (ko) | 2019-03-20 |
RU2671202C1 (ru) | 2018-10-30 |
US20180297998A1 (en) | 2018-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6359208B2 (ja) | プラジカンテル及びその中間体化合物の製造方法 | |
Subbiah et al. | Direct transformation of 5-hydroxymethylfurfural to the building blocks 2, 5-dihydroxymethylfurfural (DHMF) and 5-hydroxymethyl furanoic acid (HMFA) via Cannizzaro reaction | |
Chennapuram et al. | Group-assisted purification (GAP) chemistry for dihydrofurans: water as a medium for catalyst free synthesis in a one pot four component reaction | |
Kong et al. | Multi-component solvent-free cascade reaction of 2-cyanoacetamides: regioselective synthesis of pyridin-2-ones bearing quaternary centers | |
EP3898608A1 (en) | Process and intermediates for the synthesis of voxelotor | |
Gupta et al. | Rapid and selective synthesis of spiropyrazolines and pyrazolylphthalides employing Seyferth–Gilbert reagent | |
Reddy et al. | One-pot, multicomponent synthesis of 4H-pyrano [2, 3-c] pyrazoles in water at 25 C | |
CN103804386B (zh) | 4,5-二羟基-3-h-螺[呋喃-2,3’-吲哚]-2’-酮衍生物及其合成方法和应用 | |
Behbahani et al. | Synthesis of 2-amino-3-cyano-7-hydroxy-4H-chromenes using l-proline as a biocatalyst | |
Kalita et al. | FeCl 3· 6H 2 O catalyzed aqueous media domino synthesis of 5-monoalkylbarbiturates: water as both reactant and solvent | |
Motamedi-Asl et al. | Lactic acid as an efficient catalyst for the one-pot three-component synthesis of 1-amidoalkyl-2-naphthols under thermal solvent-free conditions | |
RU2631323C2 (ru) | Способ получения 4-бензил-1-фенетил-пиперазин-2,6-диона, промежуточное соединение и способ его получения | |
CN110818662A (zh) | 一种那布卡辛的合成方法 | |
Yuan et al. | Direct and highly stereoselective synthesis of quinolizidine iminosugars promoted by l-proline-Et 3 N | |
KR20210028665A (ko) | 일종(1r,3s)-3-아미노기-1-사이클로펜탄올 및 그 염의 제조방법 | |
CN114805235B (zh) | 一种多取代异恶唑烷酮及其中间体的合成制备方法 | |
De Sarlo et al. | Condensation of Primary Nitro Compounds to Isoxazole Derivatives: Stoichiometric to Catalytic | |
Murugavel et al. | Synthesis of 4, 5-Dihydro-N (2)-Phenylindazole from Diversely Substituted Cyclic-β-Keto Esters and Its Structural Analysis | |
JP6660393B2 (ja) | 4−シアノピペリジン塩酸塩を調製する方法 | |
CN109293544B (zh) | 恩杂鲁胺中间体化合物及其制备方法 | |
Ren et al. | Efficient and Green Synthesis of 2, 2′-(Arylmethylene) Bis-4-Pyrones in an Ionic Liquid [bmim+][BF4–] | |
CN103936744A (zh) | 肟取代环己基改性苷脲及合成方法 | |
Wang et al. | Synthesis of Aryl-bis (3-methyl-1-phenyl-5-pyrazolone-4-yl) methane in Water | |
Kovganko et al. | Synthesis of Substituted Benzyl Ethers of 1-(4-Hydroxyphenyl) oct-2-en-1-one | |
KR101590592B1 (ko) | 디피롤 케톤의 제조 방법 및 이에 의하여 제조된 디피롤 케톤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180604 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180531 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180619 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6359208 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |